Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03088904 · ClinicalTrials.gov registry record · Phase 1

Genetic and Environmental Factors in the Response to Influenza Vaccination

A Phase 1 study, sponsored by Stanford University.

Completed
Registry status
Phase 1
Development phase
109
Enrollment target

NCT03088904: Completed Phase 1 study, sponsored by Stanford University.

NCT03088904 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 109 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03088904, a Phase 1 study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 1
Development phase
109 participants
Enrollment target

Study Summary

The purpose of the study is to investigate and compare the immune responses to influenza vaccination in monozygotic (identical) and dizygotic (fraternal) twins to determine the roles of genetics and environment in the response to flu vaccination.

Interventions

  • BIOLOGICAL FluMist® Quadrivalent
  • BIOLOGICAL Fluzone® Quadrivalent vaccine

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2014-10-03
Est. Completion 2018-12-12
Phase Phase 1
Stanford University

1,744 total trials

What the finished NCT03088904 record still lists

NCT03088904 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% higher).

The record links to 0 conditions, and to 2 interventions - of which FluMist® Quadrivalent is the first listed.

NCT03088904 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03088904 about?

NCT03088904 is a clinical study titled "Genetic and Environmental Factors in the Response to Influenza Vaccination". The purpose of the study is to investigate and compare the immune responses to influenza vaccination in monozygotic (identical) and dizygotic (fraternal) twins to determine the roles of genetics and environment in the response to flu vaccination.

What is the current status of trial NCT03088904?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 109 participants. The study started on 2014-10-03. Estimated completion is 2018-12-12.

What interventions are being tested in trial NCT03088904?

The interventions under investigation include: FluMist® Quadrivalent (BIOLOGICAL), Fluzone® Quadrivalent vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT03088904?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03088904's enrollment target sits among peer trials

109 522nd of 2000 higher than 1,478 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02421380 · 109 participants · NA

    Characterization of Hyperpolarized Pyruvate MRI Reproducibility

  • NCT04526600 · 109 participants · NA

    Fidgeting and Attentional and Emotional Regulation in ADHD

  • NCT04835584 · 109 participants · Phase 1

    KRT-232 and TKI Study in Chronic Myeloid Leukemia

  • NCT06626516 · 109 participants · Phase 1

    Tebentafusp-tebn With LDT in Metastatic UM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03088904, the US trial registry maintained by the National Library of Medicine. NCT03088904 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.